Ignite Creation Date:
2024-05-06 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 12:47 PM
Study NCT ID:
NCT03548415
Status:
COMPLETED
Last Update Posted:
2022-11-14
First Post:
2018-05-22
Brief Title:
Safety Tolerability and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
Sponsor:
Ionis Pharmaceuticals Inc
Organization:
Ionis Pharmaceuticals Inc
Study Overview
Official Title:
A Double-Blind Placebo-Controlled Phase 2 Study to Assess the Safety Tolerability and Efficacy of ISIS 766720 IONIS-GHR-LRx an Antisense Inhibitor of the Growth Hormone Receptor Administered Once Every 28 Days for 16 Weeks in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands SRL
Status:
COMPLETED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to assess the safety tolerability and efficacy of IONIS-GHR-LRx in up to 60 participants with acromegaly
Detailed Description:
This short-term study assessed changes in serum insulin-like growth factor 1 IGF-1 over a 16-week treatment period in a participant population diagnosed with acromegaly being treated with long-acting somatostatin receptor ligands SRL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2017-004259-22 | EUDRACT_NUMBER | None | None |